Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Shares Shorted: Short Interest Down 83.6% in September

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) saw a large decrease in short interest in September. As of September 15th, there was short interest totaling 208 shares, a decrease of 83.6% from the August 31st total of 1,269 shares. Based on an average trading volume of 43,916 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are short sold.

Oaktree Acquisition Corp. III Life Sciences Trading Up 0.0%

Shares of OACC stock traded up $0.00 on Friday, hitting $10.78. 2,896 shares of the stock traded hands, compared to its average volume of 32,972. Oaktree Acquisition Corp. III Life Sciences has a twelve month low of $10.45 and a twelve month high of $10.88. The firm’s 50-day moving average price is $10.76 and its two-hundred day moving average price is $10.70.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.07 earnings per share (EPS) for the quarter.

Institutional Trading of Oaktree Acquisition Corp. III Life Sciences

Several institutional investors have recently made changes to their positions in the company. Empyrean Capital Partners LP grew its position in Oaktree Acquisition Corp. III Life Sciences by 20.0% in the fourth quarter. Empyrean Capital Partners LP now owns 900,000 shares of the company’s stock worth $9,522,000 after acquiring an additional 150,000 shares during the period. Sculptor Capital LP lifted its stake in shares of Oaktree Acquisition Corp. III Life Sciences by 6.1% in the 4th quarter. Sculptor Capital LP now owns 530,537 shares of the company’s stock valued at $5,613,000 after purchasing an additional 30,537 shares during the last quarter. Radcliffe Capital Management L.P. grew its holdings in shares of Oaktree Acquisition Corp. III Life Sciences by 67.1% during the 4th quarter. Radcliffe Capital Management L.P. now owns 377,065 shares of the company’s stock worth $3,989,000 after purchasing an additional 151,403 shares during the period. Lineage Point Capital LP purchased a new position in shares of Oaktree Acquisition Corp. III Life Sciences during the 4th quarter worth $2,461,000. Finally, DLD Asset Management LP increased its position in shares of Oaktree Acquisition Corp. III Life Sciences by 0.9% during the 1st quarter. DLD Asset Management LP now owns 136,735 shares of the company’s stock worth $1,447,000 after purchasing an additional 1,200 shares during the last quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Oaktree Acquisition Corp. III Life Sciences from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Oaktree Acquisition Corp. III Life Sciences has an average rating of “Sell”.

Oaktree Acquisition Corp. III Life Sciences Company Profile

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (SPAC) formed to identify and combine with a business in the life sciences sector. Unlike an operating company, it does not manufacture products or provide healthcare services of its own.

The company’s stated investment focus includes businesses involved in pharmaceuticals, biotechnology, medical devices, healthcare services and related life sciences technologies. Its objective is to complete a merger, stock purchase, asset acquisition, reorganization or similar business combination with a target company.

Oaktree Acquisition Corp.